Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas. Mira JA, et al. Antivir Ther. 2007;12(8):1225-35. Antivir Ther. 2007. PMID: 18240862
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, Martín-Rico P, Ríos-Villegas MJ, Hernández-Burruezo JJ, Merino D, López-Ruz MA, Rivero A, Muñoz L, González-Serrano M, Collado A, Macías J, Viciana P, Soriano V, Pineda JA. Mira JA, et al. J Antimicrob Chemother. 2008 Dec;62(6):1365-73. doi: 10.1093/jac/dkn420. Epub 2008 Oct 13. J Antimicrob Chemother. 2008. PMID: 18854330 Clinical Trial.
Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients.
Merchante N, de los Santos-Gil I, Merino D, González-Serrano M, Mira JA, Sanz-Sanz J, Fernández-Fuertes E, Ruiz-Morales J, del Valle J, Macías J, Moro A, Pineda JA. Merchante N, et al. Among authors: mira ja. J Hepatol. 2009 Apr;50(4):684-92. doi: 10.1016/j.jhep.2008.10.032. Epub 2008 Dec 29. J Hepatol. 2009. PMID: 19231001
Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
Mira JA, Gutiérrez-Valencia A, Gil Ide L, Merino D, Rivero A, Ríos-Villegas MJ, Delgado M, González-Serrano M, Collado A, Torres-Tortosa M, Omar M, López-Ruz MA, Macías J, Arponen S, Pineda JA. Mira JA, et al. Clin Infect Dis. 2009 Oct 15;49(8):e84-91. doi: 10.1086/605677. Clin Infect Dis. 2009. PMID: 19772388
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.
Macías J, del Valle J, Rivero A, Mira JA, Camacho A, Merchante N, Pérez-Camacho I, Neukam K, Rivero-Juárez A, Mata R, Torre-Cisneros J, Pineda JA; Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas. Macías J, et al. Among authors: mira ja. J Antimicrob Chemother. 2010 Oct;65(10):2204-11. doi: 10.1093/jac/dkq272. Epub 2010 Jul 22. J Antimicrob Chemother. 2010. PMID: 20656678
107 results